Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes

Reviewed 25 sourcesPublished by PepVault

Compounded semaglutide and tirzepatide often add B12, B6, glycine, carnitine or NAD+. Why, per FDA's copy rule, what each does, and what no study has tested.

A man in a navy henley pouring water into a glass carafe of lemon and mint at a kitchen counter
Last reviewed
Sources
25
Questions
7
Compounds
6

The short answer

Mostly for a legal reason, not a medical one. Since the shortages ended, a pharmacy may not regularly make what FDA calls "essentially a copy" of an approved drug, and an added B12, B6, glycine or L-carnitine makes a product look different. No trial has tested any of these mixes against the drug alone, and FDA says a B12 blend can still count as a copy.

Every number checked at its primary source · · 25 sources · How we research

Evidence: No clinical trial has tested a GLP-1 with any of these additives against the drug alone; the facts here come from FDA documents, the FDA-approved labels, one uncontrolled study of a mix, trials of each additive on its own, and animal studies.

A man in a navy henley pouring water into a glass carafe of lemon and mint at a kitchen counter

Why do compounded semaglutide and tirzepatide come with an additive?

The reason sits in the law, not in the vial. A state-licensed pharmacy compounding under section 503A may not regularly make a product that is "essentially a copy" of a commercially available drug2. FDA's test has three parts: the same active ingredient, a strength within 10% of the approved product's (or one easily reached with it), and a route the approved product can also be used by2. With the shortages over, a plain semaglutide or tirzepatide injection at a brand strength meets all three. How the shortages ended, date by date, is in the guide at /guides/compounded-glp-1-vs-brand, and 503A and 503B are explained at /glossary/compounding-503a-503b.

Pharmacists who studied the market put the next step plainly: once the shortages were resolved, compounders "can only legally sell unique products," and one way to be unique is to include an additional pharmaceutical ingredient3.

FDA does not accept the additive as the difference by itself. In its April 1, 2026 statement, FDA wrote that it may consider a product combining semaglutide with vitamin B12 (cyanocobalamin) essentially a copy when it is injected like the approved products and both amounts are within 10% of the strengths of the respective commercially available drugs1. What does make a product different, in FDA's 2018 guidance, is a prescriber's documented finding that the change produces a significant difference for one named patient, written as plainly as "No Dye X, patient allergy"2. A lower price does not count2. For now, FDA says it does not intend to act against a pharmacy that fills four or fewer prescriptions of such a copy in a calendar month1. As of November 20, 2026, the April 1, 2026 entry is the latest on FDA's GLP-1 compounding page1.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's bloodwork log keeps each vitamin B12 result in pg/mL with its reference range, so you and your clinician can see whether your level actually moved.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which additives show up, and how often?

In a February to March 2025 search of compounding sites, University of Connecticut pharmacists found 33 semaglutide or tirzepatide products that differed from the approved ones. Of those, 48% paired the drug with cyanocobalamin, glycine, niacinamide (a form of vitamin B3), docusate (a stool softener) or ondansetron (an anti-nausea drug)3. Their verdict on the nutrients and docusate: "little justification" for adding them3. A 2024 count of 93 Colorado websites selling compounded GLP-1s for weight loss found B vitamins offered on 8, levocarnitine (L-carnitine) on 1 and glycine on 14. Pyridoxine (vitamin B6) and NAD+ are the other two names people search with their GLP-1.

What does each additive do at the amount in a vial?

Each is a real nutrient or medicine with a real use. For most, the amounts and routes in a weekly GLP-1 shot differ from the ones studied.

AdditiveWhat it is forWhat the studies or labels usedTested with a GLP-1?
Vitamin B12 (cyanocobalamin or methylcobalamin)Making red blood cells and keeping nerves healthy; injections treat a deficiency5100 mcg injections for pernicious anemia; within 48 hours, 50 to 98% of a 100 or 1,000 mcg injection may appear in the urine5One study without a comparison group: semaglutide with 125 to 240 mcg of cyanocobalamin a week6
Vitamin B6 (pyridoxine)Nausea of pregnancy30 mg a day by mouth eased nausea in a trial of 342 pregnant women7; 10 mg in each tablet of Diclegis, an approved pregnancy-nausea pill8No
GlycineAn amino acid studied for sleep3 g by mouth before bed11; water dissolves about 250 mg per mL, so a 0.5 mL shot can carry at most about 125 mg10No
L-carnitine (levocarnitine)Carries long-chain fatty acids into mitochondria to be burned; the approved injection treats carnitine deficiency and is labeled for intravenous use only12Nine trials, 911 adults: 1.33 kg more weight lost than control13No
NAD+ and niacinamide (B3)NAD+ is a coenzyme cells use to make energy; niacinamide is one of its raw materialsBy mouth for 14 days, NR and NMN raised blood NAD+ in 65 adults; nicotinamide (niacinamide) did not14Not in people. In mice, tirzepatide alone raised NAD+ in injured kidneys15

Much of an injected B12 dose leaves in the urine within two days, by the injection label's own account5. B6's evidence is for pregnancy nausea, and even there a Cochrane review of 41 trials found only limited support for vitamin B69. Glycine's sleep dose is 3 g, about 24 times more than the most a 0.5 mL injection can dissolve1011. The nausea a GLP-1 causes is real and common: 44% on Wegovy 2.4 mg against 16% on placebo, and 25 to 29% on Zepbound against 8%2022. No study has asked whether any of these additives changes those numbers.

Species note: the tirzepatide and NAD+ finding comes from mice and from human kidney cells grown in a dish, after a chemotherapy drug injured the kidneys15.

Did any study test a GLP-1 together with these additives?

No controlled trial has. We searched PubMed and ClinicalTrials.gov on November 20, 2026 for semaglutide or tirzepatide with each additive, and found no trial that mixed an additive into the shot and compared it with the drug alone25. The nearest, an Egyptian trial (NCT06981936), tested a multivitamin tablet against placebo in GLP-1 users and posted no results25. The one outcome study of a mix followed 94 people at a commercial wellness studio on compounded semaglutide with cyanocobalamin: they lost 4.57% of their weight in 3 months6. It had no B12-free group, so it cannot say what the B12 added, and all seven authors list the wellness-clinic company that ran the program as an affiliation6.

The most interesting B12 science runs the other way. Researchers bonded a B12 precursor, dicyanocobinamide, onto exendin-4, an older GLP-1 drug. In musk shrews, animals that can vomit, the bonded drug still improved blood sugar and caused far less vomiting16. In healthy and tumor-bearing rats, it improved glucose tolerance without cutting appetite or weight17. The bond limits how much of the drug reaches the brain, where GLP-1 nausea starts1617. It is a new molecule made in a lab, not a vitamin mixed into a vial, and it has not been tested in people.

Does adding B12 change the drug in the vial?

It can. In a 2026 analysis of compounded tirzepatide and B12 products obtained on the US market, chemists found a widespread impurity formed by a chemical reaction between tirzepatide and certain forms of B12, present at substantial levels18. What that impurity does in the body is unknown18. The authors work for Eli Lilly, which makes Mounjaro and Zepbound, so the finding comes from the brand's maker; as of November 20, 2026 we found no independent published test of these mixes.

What do the Ozempic, Wegovy, Mounjaro and Zepbound labels say about vitamins?

None of the four labels names B12, B6, glycine, carnitine or NAD+ anywhere. Their interaction sections are about other things, and their patient guides ask you to tell your healthcare provider about all the medicines you take, "including prescription and over-the-counter medicines, vitamins, and herbal supplements"19202122. Each label in brief: /drugs/ozempic, /drugs/wegovy, /drugs/mounjaro and /drugs/zepbound, compared at /drugs.

LabelWhat its interaction section listsInactive ingredientsAny of the additives?
Ozempic (semaglutide)Low blood sugar risk with insulin or a sulfonylurea; slower stomach emptying may affect pills taken by mouth19Pen: disodium phosphate dihydrate, propylene glycol, phenol, water; single-dose syringe: disodium phosphate dihydrate, sodium chloride, water19No19
Wegovy (semaglutide)The same two; levothyroxine exposure rose 33% with the semaglutide tablet20Disodium phosphate dihydrate, sodium chloride, water; phenol and propylene glycol in the FlexTouch pen20No20
Mounjaro (tirzepatide)The same two; people on birth-control pills switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase21Sodium chloride, sodium phosphate dibasic heptahydrate, water; benzyl alcohol, glycerin and phenol in the multi-dose vial and KwikPen21No21
Zepbound (tirzepatide)The same as Mounjaro22The same as Mounjaro22No22

Where a B12 check does appear is the metformin label, a diabetes pill many GLP-1 users also take. In metformin trials of 29 weeks, B12 fell below normal in about 7% of patients, and the label asks for a B12 test every 2 to 3 years23. A 2026 review of GLP-1 and tirzepatide users lists B12 among the nutrients worth watching, mostly in people with prior weight-loss surgery, bowel disease, a poor diet, older age or long nausea and vomiting, and says most changes reported so far showed up only on lab tests24. A blood test answers that question for you directly.

PepVault's bloodwork log keeps each vitamin B12 result in pg/mL with its reference range, so you and your clinician can see whether your level actually moved. Log it in PepVault

What should you check if your prescription has an additive?

  1. Read every active ingredient on the vial label and its amount per mL, and keep that with your record of the product.
  2. Ask your prescriber what difference the additive makes for you. Under FDA's guidance that reason belongs on the prescription for the product not to count as a copy2.
  3. If B12 is the worry, ask for a B12 blood test rather than relying on what the vial adds.
  4. Tell your prescriber about every vitamin and supplement you take beside the shot, as each GLP-1 label's patient guide asks1921.
  5. Note any nausea with its date and strength, so a change of product can be judged on your own record.

PepVault logs each side effect with the compound, the date and how strong it felt, and puts them in the report you can share with your doctor. Log it in PepVault

Commonly reported: people moving between a B12 mix and a brand pen notice the color first. Cyanocobalamin is a dark red powder5, so a B12 blend runs pink to red, while the four labels describe a clear solution, colorless or slightly yellow19202122.

When to get help Vomiting that won't stop, belly pain that doesn't settle, or a dose that may have been larger than intended is a reason to call your prescriber the same day.

Whether a compounded blend, a plain compounded product or an approved pen fits you is a decision for you and your prescriber, with the label in front of you both.

Track it in the app

Sources

  1. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (entry of Apr 1, 2026; content current as of Apr 1, 2026; read Nov 20, 2026). fda.gov
  2. U.S. Food and Drug Administration. Compounded drug products that are essentially copies of a commercially available drug product under section 503A of the FD&C Act. Guidance for industry, January 2018. fda.gov
  3. Belcourt J, Sapowadia A, White CM. Compounded semaglutide and tirzepatide products use unique formulations but efficacy and safety largely unknown. Ann Pharmacother. 2026;60(9):902-906. PubMed 41689811
  4. DiStefano MJ et al. Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado. J Pharm Policy Pract. 2025;18(1):2441220 (online Dec 24, 2024). PubMed 39776466
  5. Cyanocobalamin Injection, USP, 1,000 mcg/mL. Prescribing information, DailyMed SPL version 3 (effective Nov 6, 2026). dailymed.nlm.nih.gov
  6. Chun E et al. Weight loss and body composition after compounded semaglutide treatment in a real world setting. Diabetes Obes Metab. 2025;27(3):1536-1543. PubMed 39776038
  7. Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1995;173(3 Pt 1):881-4. PubMed 7573262
  8. Diclegis (doxylamine succinate and pyridoxine hydrochloride) delayed-release tablets. Prescribing information, Duchesnay USA, DailyMed SPL version 15 (effective Dec 3, 2025). dailymed.nlm.nih.gov
  9. Matthews A et al. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev. 2015;(9):CD007575. PubMed 26348534
  10. National Center for Biotechnology Information. PubChem Compound Summary for CID 750, Glycine: solubility (25.0 g per 100 mL of water at 25 °C). pubchem.ncbi.nlm.nih.gov
  11. Bannai M et al. The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers. Front Neurol. 2012;3:61. PubMed 22529837
  12. Carnitor (levocarnitine) injection. Prescribing information, Leadiant Biosciences, DailyMed SPL version 19 (effective Nov 20, 2023). dailymed.nlm.nih.gov
  13. Pooyandjoo M et al. The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2016;17(10):970-6. PubMed 27335245
  14. Christen S et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026;8(1):62-73. PubMed 41540253
  15. Han C et al. Tirzepatide ameliorates cisplatin-induced acute kidney injury by restoring NAMPT/NAD+ homeostasis and enhancing Pink1-Parkin-mediated mitophagy. Biochem Pharmacol. 2026;250(Pt 2):118040. PubMed 42114682
  16. Borner T et al. Corrination of a GLP-1 receptor agonist for glycemic control without emesis. Cell Rep. 2020;31(11):107768. PubMed 32553160
  17. Cham N et al. A dicyanocobinamide conjugate of the GLP-1R agonist exendin-4 improves glucose homeostasis in tumor-bearing rats without exacerbating anorexia and weight loss. Mol Pharm. 2026;23(10):4988-4997. PubMed 42906168
  18. Jordan B et al. A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications. Expert Opin Drug Saf. 2026;25(5):837-845. PubMed 42010938
  19. Ozempic (semaglutide) injection. Prescribing information and Medication Guide, Novo Nordisk, DailyMed SPL version 20 (effective Jun 1, 2026), sections 7 and 11. dailymed.nlm.nih.gov
  20. Wegovy (semaglutide) injection and tablets. Prescribing information and Medication Guide, Novo Nordisk, DailyMed SPL version 19 (effective Jun 18, 2026), sections 6.1, 7 and 11. dailymed.nlm.nih.gov
  21. Mounjaro (tirzepatide) injection. Prescribing information and Medication Guide, Eli Lilly, DailyMed SPL version 40 (effective Aug 27, 2026), sections 7 and 11. dailymed.nlm.nih.gov
  22. Zepbound (tirzepatide) injection. Prescribing information and Medication Guide, Eli Lilly, DailyMed SPL version 40 (effective Aug 28, 2026), sections 6.1, 7 and 11. dailymed.nlm.nih.gov
  23. Metformin hydrochloride tablets. Prescribing information, DailyMed SPL version 20 (effective Nov 9, 2026), section 5.2. dailymed.nlm.nih.gov
  24. Simancas-Racines D et al. Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: mechanistic pathways, clinical signals, and a monitoring framework. Obes Pillars. 2026;19:100290. PubMed 42382663
  25. ClinicalTrials.gov. Searches for semaglutide or tirzepatide with cyanocobalamin, vitamin B12, pyridoxine, glycine, carnitine, niacinamide and NAD (run Nov 20, 2026). clinicaltrials.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo